Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine:: impact on nitric oxide metabolism

被引:355
作者
Schwedhelm, Edzard [1 ]
Maas, Renke [1 ]
Freese, Ralf [3 ]
Jung, Donald [4 ]
Lukacs, Zoltan [2 ]
Jambrecina, Alen [3 ]
Spickler, William [5 ]
Schulze, Friedrich [1 ]
Boeger, Rainer H. [1 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Clin Pharmacol Unit, Inst Expt & Clin Pharmacol & Toxicol, D-20246 Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Paediat Clin, D-20246 Hamburg, Germany
[3] MediGate GmbH, Clin Trial Ctr N, Hamburg, Germany
[4] Pharmaceut Res Serv, Cupertino, CA USA
[5] Angiogenix, Burlingame, CA USA
关键词
asymmetric dimethylarginine; flow-mediated vasodilation; L-arginine; L-citrulline; nitric oxide;
D O I
10.1111/j.1365-2125.2007.02990.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
AIMS Oral L-arginine supplementation has been used in several studies to improve endothelium-dependent, nitric oxide (NO)-mediated vasodilation. L-Arginine treatment is hampered by extensive presystemic elimination due to intestinal arginase activity. In contrast, L-citrulline is readily absorbed and at least in part converted to L-arginine. The aim of our study was to assess this metabolic conversion and its subsequent pharmacodynamic effects. METHODS In a double-blind, randomized, placebo-controlled cross-over study, 20 healthy volunteers received six different dosing regimes of placebo, citrulline, and arginine. Pharmacokinetic parameters (C-max, T-max, C-min, AUC) were calculated after 1 week of oral supplementation. The ratio of plasma L-arginine over asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase (arginine/ADMA ratio), urinary cyclic guanosine monophosphate (cGMP) and nitrate excretion rates, and flow-mediated vasodilation (FMD) was measured to assess pharmacodynamic effects. RESULTS L-Citrulline dose-dependently increased AUC and C-max of plasma L-arginine concentration more effectively than L-arginine (P < 0.01). The highest dose of citrulline (3 g bid) increased the C-min of plasma L-arginine and improved the L-arginine/ADMA ratio from 186 +/- 8 (baseline) to 278 +/- 14 [P < 0.01, 95% confidence interval (CI) 66, 121]. Moreover, urinary nitrate and cGMP were increased from 92 +/- 10 to 125 +/- 15 mu mol mmol(-1) creatinine (P=0.01, 95% CI 8, 58) and from 38 +/- 3.3 to 50 +/- 6.7 nmol mmol(-1) creatinine (P=0.04, 95% CI 0.4, 24), respectively. No treatment improved FMD over baseline. However, pooled analysis of all FMD data revealed a correlation between the increase of arginine/ADMA ratio and improvement of FMD. CONCLUSION Our data show for the first time that oral L-citrulline supplementation raises plasma L-arginine concentration and augments NO-dependent signalling in a dose- dependent manner.
引用
收藏
页码:51 / 59
页数:9
相关论文
共 42 条
  • [1] ABUMRAD NN, 2006, JAMA-J AM MED ASSOC, V295, P1238
  • [2] Bednarz Bronislaw, 2005, Kardiol Pol, V62, P421
  • [3] Effects of oral L-arginine on endothelium-dependent vasodilation and markers of inflammation in healthy postmenopausal women
    Blum, A
    Hathaway, L
    Mincemoyer, R
    Schenke, WH
    Kirby, M
    Csako, G
    Waclawiw, MA
    Panza, JA
    Cannon, RO
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (02) : 271 - 276
  • [4] Oral L-arginine improves endothelial function in healthy individuals older than 70 years
    Bode-Böger, SM
    Muke, J
    Surdacki, A
    Brabant, G
    Böger, RH
    Frölich, JC
    [J]. VASCULAR MEDICINE, 2003, 8 (02) : 77 - 81
  • [5] L-arginine-induced vasodilation in healthy humans:: Pharmacokinetic-pharmacodynamic relationship
    Bode-Böger, SM
    Böger, RH
    Galland, A
    Tsikas, D
    Frölich, JC
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (05) : 489 - 497
  • [6] Asymmetric dimethylarginine determines the improvement of endothelium-dependent vasodilation by simvastatin -: Effect of combination with oral L-arginine
    Boeger, Gerhild I.
    Rudolph, Tanja K.
    Maas, Renke
    Schwedhelm, Edzard
    Dumbadze, Ekaterina
    Bierend, Anneke
    Benndorf, Ralf A.
    Boeger, Rainer H.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (23) : 2274 - 2282
  • [7] Asymmetric dimethylarginine (ADMA):: A novel risk marker in cardiovascular medicine and beyond
    Böger, RH
    [J]. ANNALS OF MEDICINE, 2006, 38 (02) : 126 - 136
  • [8] Asymmetric dimethylarginine (ADMA):: A novel risk factor for endothelial dysfunction -: Its role in hypercholesterolemia
    Böger, RH
    Bode-Böger, SM
    Szuba, A
    Tsao, PS
    Chan, JR
    Tangphao, O
    Blaschke, TF
    Cooke, JP
    [J]. CIRCULATION, 1998, 98 (18) : 1842 - 1847
  • [9] Hypercholesterolemia impairs basal nitric oxide synthase turnover rate:: a study investigating the conversion of L-[guanidino-15N2]-arginine to 15N-labeled nitrate by gas chromatography-mass spectrometry
    Böger, RH
    Tsikas, D
    Bode-Böger, SM
    Phivthong-ngam, L
    Schwedhelm, E
    Frölich, JC
    [J]. NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2004, 11 (01): : 1 - 8
  • [10] Asymmetric dimethylarginine, and endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor
    Böger, RH
    [J]. JOURNAL OF NUTRITION, 2004, 134 (10) : 2842S - 2847S